Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.
about
Dilemma of first line regimens in metastatic pancreatic adenocarcinomaMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community settingMetastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineEconomic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancerMeta-analyses of treatment standards for pancreatic cancer.Cost-effectiveness of systemic therapies for metastatic pancreatic cancer.Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value.Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes.Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada.Diagnostic Laparoscopy Prior to Neoadjuvant Therapy in Pancreatic Cancer Is High Yield: an Analysis of Outcomes and Costs.Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial
P2860
Q28077147-096FF99A-FE14-4E9D-8D12-635A21CC5B32Q28082919-2AD8954E-69BD-44D4-B1AE-5B11B873B3A6Q33615072-37570B22-601C-4740-974B-9200B2783750Q36035888-F503DA79-D03F-444D-B15F-B666C0AD76A8Q36135938-CBCB1920-DAF5-4090-B097-BA3513DD5CA7Q36394607-EA5B56DE-BDFC-4437-97AC-C57FC3BECC3BQ36640493-E3EF557B-AA77-4314-B9DD-B1AD2707CA02Q36738570-4C45BADB-0017-44A4-8728-847A817BD6D0Q37135340-FE6EBED6-5213-4453-B915-5E3F62808B1BQ38608747-BD10D19F-9BF3-42B6-8ADE-1080CE3B8634Q38637958-1852E6B9-0B82-4136-8695-F86A580808BFQ38648133-BB5F876D-16B8-42A8-A048-5BB8A46E2358Q38910968-A2ACAC2E-61EF-4955-BC31-FFD3763C2FF9Q39365268-BFE21F7C-B67F-46AB-B816-1853279EFEFBQ40729981-F0FAE5D0-C919-477C-903E-3710C7809A2FQ41195992-A22A48C0-7A1F-480E-AF19-7D5D54E84DDEQ46446983-E41F55F7-D8BC-4C33-B14F-7888C12F6F9DQ49720607-63C36C2D-F08C-43C4-A3E1-DFB37D382548Q53752857-3A5ACCB2-AC4D-4EFB-965A-4C1B6B8162ACQ57485825-2B6A400D-CAD7-4BE0-8085-6940774F3E88
P2860
Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of folfirin ...... metastatic pancreatic cancer.
@en
Cost-effectiveness of folfirin ...... metastatic pancreatic cancer.
@nl
type
label
Cost-effectiveness of folfirin ...... metastatic pancreatic cancer.
@en
Cost-effectiveness of folfirin ...... metastatic pancreatic cancer.
@nl
prefLabel
Cost-effectiveness of folfirin ...... metastatic pancreatic cancer.
@en
Cost-effectiveness of folfirin ...... metastatic pancreatic cancer.
@nl
P2093
P2860
P356
P1433
P1476
Cost-effectiveness of folfirin ...... metastatic pancreatic cancer.
@en
P2093
P2860
P304
P356
10.3747/CO.21.1327
P577
2014-02-01T00:00:00Z